Investigating the Effect of Micardis® on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients

This study has been completed.

First Received on April 9, 2009. Last Updated on March 2, 2010 History of Changes

Sponsor:	Boehringer Ingelheim Pharmaceuticals
Information provided by:	Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00879411

Purpose

Practical experience report (PER) investigating the effect of Micardis® on the average 24h blood pressure of therapy-naive and therapy-experienced patients

Condition
Hypertension

Study Type:	Observational
Study Design:	Observational Model: Case-Only Time Perspective: Prospective
Official Title:	24h BP Under Micardis in Daily Practice

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Telmisartan

U.S. FDA Resources

Further study details as provided by Boehringer Ingelheim Pharmaceuticals:

Primary Outcome Measures:

collect significant data on powerful BP reduction of Telmisartan in the context of 24h BP reduction after a 6 to 8 week treatment period [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

drug safety, efficacy and tolerability of Telmisartan [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]

Study Start Date:	April 2009
Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years to 95 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

hypertensive patients

Criteria

Inclusion Criteria:

Patients who have recently been diagnosed with hypertension
Patients whose current blood pressure treatment are inadequate and needs to be revised are suitable for inclusion.

Exclusion Criteria:

None (according to investigator)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00879411

Show 111 Study Locations

Sponsors and Collaborators

Boehringer Ingelheim Pharmaceuticals

Investigators

Study Chair:

Boehringer Ingelheim

Boehringer Ingelheim Pharmaceuticals

More Information

No publications provided

Responsible Party:	Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
ClinicalTrials.gov Identifier:	NCT00879411 History of Changes
Other Study ID Numbers:	502.582
Study First Received:	April 9, 2009
Last Updated:	March 2, 2010
Health Authority:	Switzerland: Laws and standards

Additional relevant MeSH terms:

Hypertension
Vascular Diseases
Cardiovascular Diseases
Telmisartan
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists

Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on February 09, 2012